唑来膦酸联合化疗治疗非小细胞肺癌骨转移的疗效观察

Effect of zoledronic acid injection and vinorelbine combined with cisplatin on non-small cell lung cancer with bone metastases

目的探讨唑来膦酸注射液配合长春瑞滨联合顺铂化疗治疗非小细胞肺癌(NSCLC)骨转移的疗效。方法将48例非小细胞肺癌骨转移患者随机分为唑来膦酸注射液加化疗组(治疗组)及单纯化疗组(对照组)各24例,治疗组接受包括唑来膦酸治疗、化疗、支持治疗的综合治疗,观察骨转移灶改变情况,疼痛改善情况,血清AKP、血清钙以及肌酐的改变情况。对照组接受化疗及支持治疗,且化疗方案同治疗组。两组患者在治疗两个周期后评价疗效,对比两组的疼痛缓解率、血清AKP、血清钙以及肌酐的变化。结果治疗组的疼痛缓解率明显高于对照组,且治疗组血清AKP、血清钙在治疗后明显下降(均P<0.05);血清肌酐在治疗前后无明显改变(P>0.05)。结论唑来膦酸治疗非小细胞肺癌骨转移止疼效果好,安全且不良反应较小,与化疗配合效果更佳。

Objective To explore the effect of zoledronic acid injection and vinorelbine combined with cisplatin on non-small cell lung cancer with bone metastases. Methods 48 patients with non-small cell lung cancer and bone metastasis were ran- domly divided into treatment group treated with zoledronic acid injection and vinorelbine combined with cisplatin （24 cases） and control group treated with of pure chemotherapy group （24 cases）. The treatment of treatment group included zoledronic acid injection and vinorelbine combined with cisplatin, support of comprehenslve treatment. The improvement of bone metastases pain to the situation, AKP, serum calcium and serum creatinine were observed. The control group was treated with chemotherapy and support treatment. The curative effect, pain relief rate, the change of AKP, serum calcium and serum creatinine were observed. Results Pain remission rate of treatment group was obviously higher than that of control group. The serum AKP and serum calcium of the treatment group significantly decreased after treatment. Serum creatinine has no obvious change before and after therapy. Conclusion Zotedronic acid injection to treat non-small cell lung cancer （NSCLC） bone metastases is effective and safe.